Last reviewed · How we verify
clarithromycin-based triple therapy
Clarithromycin-based triple therapy combines a macrolide antibiotic with two other agents (typically a proton pump inhibitor and amoxicillin or metronidazole) to eradicate Helicobacter pylori infection.
Clarithromycin-based triple therapy combines a macrolide antibiotic with two other agents (typically a proton pump inhibitor and amoxicillin or metronidazole) to eradicate Helicobacter pylori infection. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | clarithromycin-based triple therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Macrolide antibiotic combination therapy |
| Target | Bacterial 50S ribosome (clarithromycin component) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, while the companion agents work synergistically to reduce gastric acid and provide additional bactericidal activity. This combination approach increases eradication rates by targeting the pathogen through multiple mechanisms simultaneously, reducing antibiotic resistance development.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Headache
- Vomiting
Key clinical trials
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: